TY - JOUR
T1 - Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon
AU - Kawai, Yusuke
AU - Hisamatsu, Kenichi
AU - Matsubara, Hiromi
AU - Dan, Kazuhiro
AU - Akagi, Satoshi
AU - Miyaji, Katsumasa
AU - Munemasa, Mitsuru
AU - Fujimoto, Yoshihisa
AU - Kusano, Kengo F.
AU - Ohe, Tohru
PY - 2009/4
Y1 - 2009/4
N2 - Aims: To determine the effect of intravenous administration of nicorandil on slow coronary flow (SCF) phenomenon in patients undergoing percutaneous coronary intervention (PCI).Methods and resultsIn a preliminary study, 6 mg of nicorandil showed optimal efficacy for vasodilatation without causing significant haemodynamic instability. In the main study, a total of 408 patients were randomly assigned to receive intravenous administration of 6 mg of nicorandil immediately before PCI. The number of patients in the nicorandil group was 206 [acute coronary syndrome (ACS): 47, non-ACS: 159] and that in the control group was 202 (ACS: 61, non-ACS: 141). Nicorandil significantly decreased the incidence of post-procedural SCF phenomenon in both the ACS and non-ACS groups. The rate of target vessel revascularization (TVR) was significantly lower in the nicorandil group than in the control group in ACS patients.ConclusionOur simple procedure prevented SCF phenomenon not only in patients with ACS but also in patients with non-ACS without any adverse effect. Additionally our procedure reduced the rate of TVR in patients with ACS.
AB - Aims: To determine the effect of intravenous administration of nicorandil on slow coronary flow (SCF) phenomenon in patients undergoing percutaneous coronary intervention (PCI).Methods and resultsIn a preliminary study, 6 mg of nicorandil showed optimal efficacy for vasodilatation without causing significant haemodynamic instability. In the main study, a total of 408 patients were randomly assigned to receive intravenous administration of 6 mg of nicorandil immediately before PCI. The number of patients in the nicorandil group was 206 [acute coronary syndrome (ACS): 47, non-ACS: 159] and that in the control group was 202 (ACS: 61, non-ACS: 141). Nicorandil significantly decreased the incidence of post-procedural SCF phenomenon in both the ACS and non-ACS groups. The rate of target vessel revascularization (TVR) was significantly lower in the nicorandil group than in the control group in ACS patients.ConclusionOur simple procedure prevented SCF phenomenon not only in patients with ACS but also in patients with non-ACS without any adverse effect. Additionally our procedure reduced the rate of TVR in patients with ACS.
KW - Acute coronary syndrome
KW - Nicorandil
KW - Percutaneous coronary intervention
KW - Slow coronary flow phenomenon
UR - http://www.scopus.com/inward/record.url?scp=64849095094&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64849095094&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehp077
DO - 10.1093/eurheartj/ehp077
M3 - Article
C2 - 19276198
AN - SCOPUS:64849095094
SN - 0195-668X
VL - 30
SP - 765
EP - 772
JO - European Heart Journal
JF - European Heart Journal
IS - 7
ER -